Impact Factor
4.48
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.24
7,210 total citations
h5-index
71
h5 depth signal
Cited share
85.3%
1,029 of 1,207
Total citations
7,210
Citation footprint
Metric signal
7.04
External metric anchor
Self-citation
7.3%
525 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,681
China
1,034
United Kingdom
980
Denmark
522
Germany
512
Citing Fields of Research
Diabetes
4,500
Nutrition & Dietetics
582
Endocrinology & Metabolism
395
Cardiology
330
Kidney Diseases
279
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
7,828
Articles tracked across the journal lifetime
Indexed publication set
1,207
1,029 cited publications
Last 12 months
1,234
102.8 publications/month
Open access share
52.5%
648 OA publications in the last year
Leading citing country
United States
1,681 citing publications
Leading citing field
Diabetes
4,500 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 1999-
v1n1, Jan. 1999-
Active Coverage
Research Focus & Classification
Indexed Subjects
Diabetes
Broad Categories
Endocrinology
Metabolism
Diabetes
MeSH Descriptors
Diabetes Mellitus
Obesity
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1111/dom.71465
Open DOI
Rethinking Acute Glucose Rescue in Postbariatric Hypoglycaemia
03
DOI 10.1111/dom.71452
Open DOI
Impact of DBLG1 Hybrid Closed‐Loop Software Optimization and Meal Declaration Pattern on Glucose Metrics in Type 1 Diabetes: A 12‐Month Prospective Evaluation in 2014 Users
Background: The meal period is critical for the outcome of automated insulin delivery. Our aim was to explore the long‐term impact on glucose metrics of algorithmic modifications of the DBLG1 hybrid closed‐loop system, with special empha...
04
DOI 10.1111/dom.71448
Open DOI
Real‐World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1‐Year Persistence
Aims: Little is known about how glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are initiated in real‐world settings and whether prescribing behaviours in routine care contribute to the high discontinuation rates seen in practice. We...
05
DOI 10.1111/dom.71467
Open DOI
Interpreting Survodutide Renoprotection in a Hyperfiltration Model
06
DOI 10.1111/dom.71432
Open DOI
Changes in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta‐Analysis of Handgrip Strength
Aims: To systematically review and quantitatively synthesize within‐group changes in skeletal muscle strength following semaglutide treatment in adults. Materials and Methods: This PRISMA 2020 systematic review was registered in PROSPERO...
07
Aims: To compare cardiovascular outcomes associated with the initiation of insulin degludec versus insulin glargine using a target trial emulation approach in nationwide real‐world data. Materials and Methods: We conducted a nationwide o...
08
09
DOI 10.1111/dom.71447
Open DOI
A Clinically Occult Tubular Phenotype in Type 2 Diabetes Despite Normoalbuminuria and Preserved eGFR : Multiscale Human Kidney Evidence
Aims: To determine the prevalence of a low‐molecular‐weight protein (LMWP)‐defined tubular phenotype in adults with Type 2 diabetes, normoalbuminuria and preserved estimated glomerular filtration rate (eGFR), its relation to UACR, and it...
10
DOI 10.1111/dom.71460
Open DOI
Joint Assessment of Pain Relief and Tolerability After Switching to Crisugabalin
Bibliographical & Catalog Notes
Title from cover.
Has occasional supplements.
Also issued online.
v. 1, no. 1 (1999)20001127 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper